Navigation Links
Evaluating That Thing On Your Skin Just Got a Whole Lot Easier
Date:11/5/2013

BOSTON, Nov. 5, 2013 /PRNewswire/ -- Olay® facial cream's famous motto was "Love the skin you're in." We should, since our largest organ does so much for us. Skin acts as a waterproof insulating shield, guarding the body against extremes of temperature, damaging sunlight and harmful chemicals. It exudes antibacterial substances that prevent infection, and manufactures vitamin D for converting calcium into healthy bones. Skin is also a huge sensor, packed with nerves for keeping the brain in touch with the outside world. But loving the skin we're in is actually easier said than done, because of the ever-present possibility of skin cancer. 

This is an understandable concern, with the American Cancer Society reporting there are more than 3.5 million skin cancers diagnosed each year—more than all other cancers combined. This makes us leery of every suspicious lump, mole, skin tag or discoloration on the body. We also worry that our doctor might overlook a potentially cancerous lesion; or if not, that the biopsy will be painful and leave us with a visible scar. Scarring does happen, even if that suspicious lesion is benign.

Is there an answer to this all-too-prevalent dilemma?

Now there is, thanks to a remarkable advance in medical instrumentation. Based in Boston and Rochester, Caliber Imaging & Diagnostics (Caliber I.D.) is a leader in noninvasive optical biopsies—i.e., its technology can capture high-resolution images providing doctors with cellular views at varying depths under the skin, enabling an accurate real-time diagnosis. Caliber I.D. has created and is already marketing a suite of its FDA-cleared devices, known as VivaScope® confocal imaging systems.

Since there is no cutting involved with VivaScope, there is also no possibility of infection or scarring. Obtaining an image takes just a few minutes so the doctor can make a determination at the bedside, or the image can be transferred within minutes through the company's VivaNet® system, so that a pathologist can diagnose it remotely.

Enthusiastic users include prestigious hospitals and many other leading academic institutions, private physicians' practices and Fortune 500 companies. As CEO L. Michael Hone explains, "The VivaScopes allow physicians to nondestructively examine tissue to determine whether it is responding to therapy; or, when surgery has been performed, to quickly and efficiently examine the skin surrounding the excised cancerous lesion."

Hone adds, "Consult your healthcare provider immediately when you spot anything you think might be questionable. When you see your doctor, you might want to ask if he or she has a VivaScope, the noninvasive way to biopsy your skin."  

For more on this major advance, visit www.caliberid.com, who paid for the writing and dissemination of this release.

Contact: Laura Radocaj, Dian Griesel Int'l., 212.825.3210

 


'/>"/>
SOURCE Caliber I.D.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
2. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
3. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
5. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
6. Study Showcases Effective Approaches for Evaluating the Performance of Executives who Handle Managed Markets Accounts
7. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
8. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
9. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
10. AtheroMed Announces Completion of Patient Enrollment in the EASE Study Evaluating the Phoenix Atherectomy System in Treating PAD
11. AtheroMed Announces Results Of The EASE Study Evaluating The Phoenix Atherectomy System In Treating Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Pa. , Oct. 12, 2017 ... leader in innovative solutions for injectable drug administration, today ... before the market opens on Thursday, October 26, 2017, ... the results and business expectations at 9:00 a.m. Eastern ... (U.S.) or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
Breaking Medicine News(10 mins):